U.S. FDA Grants Priority Review of INVOKANA ® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news

Related Links:

Nature Reviews Nephrology, Published online: 24 June 2019; doi:10.1038/s41581-019-0173-0Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been recommended for the treatment of patients with type 2 diabetes mellitus and cardiovascular disease, heart failure or chronic kidney disease. Findings from recent efficacy and safety trials of empagliflozin in kidney transplant recipients with post-transplantation diabetes are timely, given the elevated cardiovascular risk associated with solid organ transplantation.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research
AbstractPurpose of ReviewNon-dialysis-dependent chronic kidney disease (NDD-CKD) patients are at an increased risk of cardiovascular disease (CVD) –related deaths in comparison with the general population. This review summarizes recent guideline recommendations and studies on primary and secondary prevention of traditional cardiovascular (CV) risk factors in those with NDD-CKD.Recent FindingsThe use of antiplatelet agents for primary prevention in CKD is not supported by clinical trial evidence; however, they offer potential benefits when used for secondary prevention of CVD in the absence of an elevated bleeding ris...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
Linagliptin demonstrated"reassuring" cardiovascular and renal safety in patients with type 2 diabetes, even among those who were older or had severe chronic kidney disease, researchers report.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Authors: Li AA, Ahmed A, Kim D Abstract Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and encompasses a spectrum of pathology from simple steatosis to inflammation and significant fibrosis that leads to cirrhosis. NAFLD and its comorbid conditions extend well beyond the liver. It is a multisystemic clinical disease entity with extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, chronic kidney disease, hypothyroidism, polycystic ovarian syndrome, and psoriasis. Indeed, the most common causes of mortality in subjects with NAFLD are cardiovascular disease, f...
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
Authors: Tanner C, Wang G, Liu N, Andrikopoulos S, Zajac JD, Ekinci EI Abstract ■Metformin is recommended as first-line therapy for type 2 diabetes because of its safety, low cost and potential cardiovascular benefits. ■The use of metformin was previously restricted in people with chronic kidney disease (CKD) - a condition that commonly coexists with diabetes - due to concerns over drug accumulation and metformin-associated lactic acidosis. ■There are limited data from observational studies and small randomised controlled trials to suggest that metformin, independent of its antihyperglycaemic effects, may be ...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
CONCLUSION: The association of normoalbuminuria is common in DKD. The decline of renal function is slower in normoalbuminuria; however, the risk factors, clinical progression, and renal pathology in these patients need to be further explored.
. PMID: 31198168 [PubMed - as supplied by publisher]
Source: Clinical Nephrology - Category: Urology & Nephrology Authors: Tags: Clin Nephrol Source Type: research
Guidelines used by GPs to monitor chronic diseases are based on expert opinion rather than evidence, according to a review of the guidelines by National Institute for Health Research (NIHR) researchers at the University of Bristol. The review, published today [Thursday 13 June] in the British Medical Journal, looked at guidelines for chronic kidney disease, high blood pressure and type 2 diabetes, which are monitored through a range of tests in GP surgeries.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, Research, International; Faculty of Health Sciences, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Abstract While rates of ischemic complications in type 2 diabetes mellitus seem to be declining, some of the most feared and costly complications, namely end-stage kidney disease (ESKD), heart failure, and lower limb amputations, remain on the rise. Herein, we discuss how the results from the Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE) trial may change this calculus.1 The development of chronic kidney disease (CKD) in type 2 diabetes mellitus marks the beginning of a sharp increase in cardio-renal complications.2 Indeed, in ty...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuriaFindings from a post-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and chronic kidney disease without overt proteinuria were presented at the 79th American Diabetes Association Scientific Sessions®
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Canagliflozin | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Grants | Invokana | Pharmaceuticals | Urology & Nephrology